34718963|t|Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study.
34718963|a|BACKGROUND: Parkinson's disease-related psychosis increases patients' risk of falls. Pimavanserin is an atypical antipsychotic approved in the USA in 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease-related psychosis. OBJECTIVE: We aimed to compare the risk of falls/fractures among patients with Parkinson's disease-related psychosis treated with pimavanserin vs other atypical antipsychotics. PATIENTS AND METHODS: We identified a cohort of patients with Parkinson's disease-related psychosis aged >= 40 years initiating either pimavanserin or a comparator antipsychotic (clozapine, quetiapine, risperidone, olanzapine, aripiprazole, brexpiprazole) in US commercial insurance and supplementary Medicare claims (2015-2019). Comparators were propensity score matched 2:1 with pimavanserin initiators; incidence rates of falls/fractures were compared using incidence rate ratios (IRRs) and 95% confidence intervals (CIs). RESULTS: We identified 112 eligible pimavanserin initiators and 982 comparators. Pimavanserin initiators were younger and had fewer severe comorbidities, indicators of impairment, and healthcare encounters, though they had higher Parkinson's disease medication use. The crude incidence rates [cases/100 person-years] (95% CI) for composite falls/fractures were 17.8 (7.7-35.0) for pimavanserin and 40.8 (35.0-47.4) for comparators. Matching retained 108 pimavanserin initiators and 216 comparators-all characteristics were well balanced after matching-with a matched IRR (pimavanserin vs comparator) of 0.71 (95% CI 0.27-1.67). Sensitivity analysis IRR estimates were consistently below 1.00, with a sensitivity analysis not requiring a diagnosis of psychosis resulting in an IRR estimate of 0.55 (95% CI 0.34-0.86). CONCLUSIONS: The results of this study do not suggest an increase in the risk of falls or fractures associated with pimavanserin compared with other antipsychotics in patients with Parkinson's disease-related psychosis. Sensitivity analyses suggest a decreased risk.
34718963	0	19	Falls and Fractures	Disease	MESH:C537863
34718963	23	31	Patients	Species	9606
34718963	37	56	Parkinson's Disease	Disease	MESH:D010300
34718963	65	74	Psychosis	Disease	MESH:D011618
34718963	88	100	Pimavanserin	Chemical	MESH:C510793
34718963	157	176	Parkinson's disease	Disease	MESH:D010300
34718963	185	194	psychosis	Disease	MESH:D011618
34718963	205	213	patients	Species	9606
34718963	223	228	falls	Disease	MESH:C537863
34718963	230	242	Pimavanserin	Chemical	MESH:C510793
34718963	321	335	hallucinations	Disease	MESH:D006212
34718963	340	349	delusions	Disease	MESH:D063726
34718963	366	385	Parkinson's disease	Disease	MESH:D010300
34718963	394	403	psychosis	Disease	MESH:D011618
34718963	448	453	falls	Disease	MESH:C537863
34718963	454	463	fractures	Disease	MESH:D050723
34718963	470	478	patients	Species	9606
34718963	484	503	Parkinson's disease	Disease	MESH:D010300
34718963	512	521	psychosis	Disease	MESH:D011618
34718963	535	547	pimavanserin	Chemical	MESH:C510793
34718963	582	590	PATIENTS	Species	9606
34718963	630	638	patients	Species	9606
34718963	644	663	Parkinson's disease	Disease	MESH:D010300
34718963	672	681	psychosis	Disease	MESH:D011618
34718963	717	729	pimavanserin	Chemical	MESH:C510793
34718963	761	770	clozapine	Chemical	MESH:D003024
34718963	772	782	quetiapine	Chemical	MESH:D000069348
34718963	784	795	risperidone	Chemical	MESH:D018967
34718963	797	807	olanzapine	Chemical	MESH:D000077152
34718963	809	821	aripiprazole	Chemical	MESH:D000068180
34718963	823	836	brexpiprazole	Chemical	MESH:C000591922
34718963	963	975	pimavanserin	Chemical	MESH:C510793
34718963	1007	1012	falls	Disease	MESH:C537863
34718963	1013	1022	fractures	Disease	MESH:D050723
34718963	1144	1156	pimavanserin	Chemical	MESH:C510793
34718963	1189	1201	Pimavanserin	Chemical	MESH:C510793
34718963	1338	1357	Parkinson's disease	Disease	MESH:D010300
34718963	1448	1453	falls	Disease	MESH:C537863
34718963	1454	1463	fractures	Disease	MESH:D050723
34718963	1489	1501	pimavanserin	Chemical	MESH:C510793
34718963	1562	1574	pimavanserin	Chemical	MESH:C510793
34718963	1680	1692	pimavanserin	Chemical	MESH:C510793
34718963	1858	1867	psychosis	Disease	MESH:D011618
34718963	2006	2011	falls	Disease	MESH:C537863
34718963	2015	2024	fractures	Disease	MESH:D050723
34718963	2041	2053	pimavanserin	Chemical	MESH:C510793
34718963	2092	2100	patients	Species	9606
34718963	2106	2125	Parkinson's disease	Disease	MESH:D010300
34718963	2134	2143	psychosis	Disease	MESH:D011618
34718963	Negative_Correlation	MESH:D000069348	MESH:D011618
34718963	Positive_Correlation	MESH:C510793	MESH:D050723
34718963	Negative_Correlation	MESH:C510793	MESH:D006212
34718963	Negative_Correlation	MESH:C000591922	MESH:D010300
34718963	Negative_Correlation	MESH:C510793	MESH:D010300
34718963	Negative_Correlation	MESH:D000068180	MESH:D011618
34718963	Negative_Correlation	MESH:D000077152	MESH:D011618
34718963	Negative_Correlation	MESH:C510793	MESH:D063726
34718963	Negative_Correlation	MESH:D018967	MESH:D011618
34718963	Negative_Correlation	MESH:C510793	MESH:D011618
34718963	Negative_Correlation	MESH:D003024	MESH:D011618
34718963	Positive_Correlation	MESH:C510793	MESH:C537863
34718963	Negative_Correlation	MESH:C000591922	MESH:D011618

